30 closest matches · ranked by relevance
Drug-Drug Interaction · Healthy Volunteers
Primary: Lovastatin AUC in the Presence of Fluoxetine — 170; 180 nmol*hr/L — p=>0.05
Opioid Use · Sedative Use
Primary: Change in Subject-Rated Outcome: Visual Analog Scale (VAS) Drug Liking — 7.40; 39.00; 40.80; 24.50 Score on a scale — p=<0.0001
Alpha 1 Antitrypsin Deficiency
Primary: Changes in Inflammatory Biomarkers in Bronchoalveolar Lavage Fluid — 14.3; 8.1; 10.3; 379.9 pg/ml — p=<0.05
Cocaine Addiction
Primary: Cocaine Use — 58.9; 71.57; 69.63; 121.25 Dollar amounts of cocaine use
Alzheimer's Disease · Dementia
Primary: Medication Appropriateness Index — 11.2; 9.4 units on a scale
Parkinson Disease
Primary: Number of Subjects Who Develop an Adverse Event During the 7-week Treatment Period That is Determined to be Likely Related to the Study Medications. — 8 Participants
Hypertension
Primary: Change in Blood Pressure During High Salt Intake and Fenofibrate Treatment Compared to High Salt Intake and Placebo Treatment — 2.0; -3.4 mm Hg
Methamphetamine Use Disorder
Primary: Reinforcing Effects of Methamphetamine Following Methylphenidate (0 mg; Placebo) Maintenance. — 0; 0; 3.33; 7.25 Trials Completed
Drug Interactions
Primary: Difference in Clinically Significant Visual Analogue Scale for Pain and Nausea Change Between CYP2D6 Users and Non-users — 7.4; 10.9; -14.0 millimeters
Hypertension
Primary: Change of Sitting Blood Pressure — -10.19; -19.88; -10.13; -4.30 mm Hg
Healthy
Primary: Area Under the Curve 0 to Infinity (AUC0-∞) — 5190; 5340 nmol*h/L
Pulmonary Arterial Hypertension
Primary: Characterisation of Medication Levels — 5.54; 2.18; 1.81; 1.53 MOM
Healthy
Primary: NK-104 AUC — 208.92 ng * h/mL
Polypharmacy
Primary: Number of Participants With Changes in Signs and Symptoms Related to Adverse Effects of Prescribed Medicines. Clinical Gains and Benefits to Residents — 17 Participants
Opioid Abuse
Primary: Subjective Ratings of "Good" Drug Effect — 37; 35; 35 units on a scale
Sepsis
Primary: Imipenem Clearance — 17.31 L/h
Alcohol Use Disorder
Primary: Reinforcing Effects (Pre-Alcohol Dose Consumption) — 0.005; .01; 0.007; 0.005 Units on a Theoretical Scale
Hypertriglyceridemia
Primary: Percent Change in Plasma Triglycerides (Pharmacodynamic Population) — -20.9; -18.3 Percent Change from baseline
Cocaine Dependence
Primary: Attentional Bias as Assessed by Score on the Stroop Task — -13.90333; 27.118; -9.361269; 15.35407 milliseconds
Cocaine Dependence · Opioid Dependence
Primary: Urine Toxicology for Cocaine. — 84; 68; 56; 67 % cocaine + urines over 2 week blocks
Parkinson's Disease (PD)
Primary: Maximum Observed Plasma Drug Concentration (Cmax) — 1.28; 1.45; 1.42; 0.439 ng/mL
Type 2 Diabetes Mellitus
Primary: Increased HDL-Cholesterol and Decreased Triglycerides — 7.9; 2.7; 15.7; -1.5 % Change — p=0.05
Arrhythmia · Atrial Fibrillation · Atrial Flutter
Primary: Relationship Between Amiodarone Concentration in Fat Tissue and Cumulated Dose. — 0.20 Correlation coefficient R
Healthy Volunteers
Primary: Maximum Level of Sedation for Lorazepam 1 mg IM + ADASUVE 10 mg — 12.3 units on a scale
Epilepsies, Partial
Primary: Number of Participants With Treatment-Related Adverse Events Unexpected From Japanese Package Insert — 27 participants
Parkinson's Disease (PD)
Primary: Cmax - Maximum Observed Plasma Concentration of Levodopa — 314; 266; 263; 260 ng/mL
Cocaine Dependence
Primary: Number of Choices to Self-administer Cocaine (Out of 5 Choices) — 1.61; 4.33 number of cocaine choices
Drug-drug Interaction
Primary: AUC — 242; 642; 124; 371 ng/mL·h
Healthy
Primary: Area Under the Curve of Digoxin From 0 to Last Quantifiable Data Point (AUC 0-tz) — 11.549; 11.981 nanomole hour per liter (nmol·h/L)
Pharmacokinetics
Primary: AUC (0-inf) — 126.47; 223.63 h*pg/mL